US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
DE4243279A1
(de)
*
|
1992-12-21 |
1994-06-23 |
Bayer Ag |
Substituierte Triole
|
DE4244029A1
(de)
*
|
1992-12-24 |
1994-06-30 |
Bayer Ag |
Neue substituierte Pyridine
|
DE4309553A1
(de)
*
|
1993-03-24 |
1994-09-29 |
Bayer Ag |
Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
|
DE69527684T2
(de)
*
|
1994-09-06 |
2002-11-28 |
Ube Industries, Ltd. |
Herstellung von 3-oxy-5-oxo-6-Heptensäurederivaten
|
BR9708672A
(pt)
|
1996-04-16 |
1999-08-03 |
Bayer Ag |
D-manitol e sua preparação
|
DE19627420A1
(de)
*
|
1996-07-08 |
1998-01-15 |
Bayer Ag |
6-(Hydroxymethyl-ethyl)pyridine
|
DE19714343A1
(de)
|
1997-04-08 |
1998-10-15 |
Bayer Ag |
Chromatographische Enantiomerentrennung von Lactonen
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
AU757104B2
(en)
|
1998-06-24 |
2003-01-30 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
DE19858789A1
(de)
*
|
1998-12-18 |
2000-06-21 |
Bayer Ag |
Kombination von Cerivastatin und Fibraten
|
US6569461B1
(en)
*
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
GB0003305D0
(en)
*
|
2000-02-15 |
2000-04-05 |
Zeneca Ltd |
Pyrimidine derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
AU2001257022B2
(en)
*
|
2000-04-13 |
2005-02-03 |
Mayo Foundation For Medical Education And Research |
Abeta 42 lowering agents
|
US6812345B2
(en)
|
2000-06-15 |
2004-11-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US20020013334A1
(en)
*
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
US6627636B2
(en)
|
2000-06-15 |
2003-09-30 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
JO2654B1
(en)
|
2000-09-04 |
2012-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Multiple aryl caroxa amides are useful as lipid - lowering agents
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
WO2002030425A1
(fr)
*
|
2000-10-12 |
2002-04-18 |
Nissan Chemical Industries, Ltd. |
Medicaments pour la prevention ou le traitement de complications du diabete
|
JO2409B1
(en)
*
|
2000-11-21 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Second-phenyl carboxy amides are useful as lipid-lowering agents
|
US20040063961A1
(en)
*
|
2000-12-21 |
2004-04-01 |
Van Der Schaaf Paul Adriaan |
Crystalline forms of cerivastatin sodium
|
JO2390B1
(en)
|
2001-04-06 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Diphenylcarboxamides act as lipid-lowering agents
|
HUP0600232A2
(en)
|
2001-04-11 |
2006-08-28 |
Bristol Myers Squibb Co |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
AU2002257147B9
(en)
*
|
2001-04-18 |
2005-08-18 |
Genzyme Corporation |
Methods of treating syndrome X with aliphatic polyamines
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
KR20040026705A
(ko)
*
|
2001-08-16 |
2004-03-31 |
테바 파마슈티컬 인더스트리즈 리미티드 |
스타틴의 칼슘 염 형태의 제조 방법
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
RU2353625C2
(ru)
*
|
2001-10-18 |
2009-04-27 |
Бристол-Маерс Сквибб Компани |
Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
AU2002367060A1
(en)
*
|
2001-12-21 |
2003-07-30 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
AU2002351412B2
(en)
*
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
US20050113577A1
(en)
*
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
DE10216967A1
(de)
*
|
2002-04-16 |
2003-11-13 |
Bayer Ag |
Verfahren zur Herstellung spezieller aromatischer Aldehyde
|
US6747048B2
(en)
|
2002-05-08 |
2004-06-08 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
KR101069781B1
(ko)
*
|
2002-05-14 |
2011-10-05 |
프라샌트 인베스트먼츠, 엘엘씨 |
전송 신호를 생성하는 방법
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
AU2003241477A1
(en)
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
AU2003254354A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances
|
UA79300C2
(en)
|
2002-08-12 |
2007-06-11 |
Janssen Pharmaceutica Nv |
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
DE60332856D1
(de)
*
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
ATE407670T1
(de)
|
2002-12-20 |
2008-09-15 |
Pfizer Prod Inc |
Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
US20040186046A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
US20040254238A1
(en)
*
|
2003-04-07 |
2004-12-16 |
Osteoscreen |
Bone growth stimulation with NO/statin and other NO modulating combinations
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7368468B2
(en)
*
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
KR20060024428A
(ko)
*
|
2003-06-18 |
2006-03-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
플루바스타틴 나트륨 결정 형태, 이것의 제조 방법, 상기결정 형태를 포함하는 조성물 및 상기 결정 형태를이용하는 방법
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
AU2004266740B2
(en)
|
2003-08-21 |
2010-08-26 |
Merck Frosst Canada Ltd |
Cathepsin cysteine protease inhibitors
|
EP1562912A2
(en)
*
|
2003-08-28 |
2005-08-17 |
Teva Pharmaceutical Industries Limited |
Process for preparation of rosuvastatin calcium
|
KR20060111898A
(ko)
*
|
2003-08-29 |
2006-10-30 |
교와 가부시키가이샤 |
지질-풍부-플라크의 안정화 방법 및 파열 예방방법
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CA2545311C
(en)
*
|
2003-11-12 |
2012-01-03 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
CA2546701C
(en)
*
|
2003-11-24 |
2010-07-27 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
US8415364B2
(en)
*
|
2003-11-26 |
2013-04-09 |
Duke University |
Method of preventing or treating glaucoma
|
ATE507209T1
(de)
*
|
2003-12-02 |
2011-05-15 |
Teva Pharma |
Referenzstandard zur charakterisierung von rosuvastatin
|
US20070179166A1
(en)
*
|
2003-12-24 |
2007-08-02 |
Valerie Niddam-Hildesheim |
Process for preparation of statins with high syn to anti ratio
|
US20050159615A1
(en)
*
|
2003-12-24 |
2005-07-21 |
Entire Interest. |
Process for preparation of statins with high syn to anti ratio
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
EP1559419A1
(en)
*
|
2004-01-23 |
2005-08-03 |
Fournier Laboratories Ireland Limited |
Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
EP1563837A1
(en)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
|
EP1719525B1
(en)
*
|
2004-02-25 |
2014-12-10 |
Kowa Company, Ltd. |
Nuclear transfer promoter for cdc42 protein and method of screening the same
|
EP1719524B1
(en)
*
|
2004-02-25 |
2014-11-26 |
Kowa Company, Ltd. |
Nuclear transfer promoter for rac protein and method of screening the same
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
MXPA06012165A
(es)
*
|
2004-04-29 |
2007-01-17 |
Keystone Retaining Wall System |
Chapas para muros, muros de contencion y similares.
|
AU2005247195A1
(en)
*
|
2004-05-27 |
2005-12-08 |
Dexcel Pharma Technologies Ltd |
Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
JP2008505975A
(ja)
*
|
2004-07-12 |
2008-02-28 |
フェノミックス コーポレーション |
制約されたシアノ化合物
|
CA2573857A1
(en)
*
|
2004-07-13 |
2006-02-16 |
Teva Pharmaceutical Industries Ltd. |
A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006017698A2
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
JP2008516890A
(ja)
*
|
2004-08-06 |
2008-05-22 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なフェノフィブラート製剤および関連治療方法
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
WO2006045008A2
(en)
*
|
2004-10-19 |
2006-04-27 |
Cargill, Incorporated |
Meat having increased level of hdl
|
US20090196889A1
(en)
*
|
2004-11-22 |
2009-08-06 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
RU2394820C2
(ru)
|
2004-12-09 |
2010-07-20 |
Мерк Шарп Энд Домэ Корп. |
Модуляторы рецептора эстрогена
|
TW200619204A
(en)
*
|
2004-12-10 |
2006-06-16 |
Kowa Co |
Method for reduction, stabilization and prevention of rupture of lipid rich plaque
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076569A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
ATE421518T1
(de)
*
|
2005-02-10 |
2009-02-15 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
EP1851206B1
(en)
*
|
2005-02-22 |
2012-08-15 |
Teva Pharmaceutical Industries, Ltd. |
Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
DK1855674T3
(da)
|
2005-03-02 |
2014-10-20 |
Merck Sharp & Dohme |
Sammensætning til hæmning af cathepsin k
|
AU2006228525A1
(en)
*
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AR053495A1
(es)
*
|
2005-05-26 |
2007-05-09 |
Bristol Myers Squibb Co |
Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
KR20080039876A
(ko)
*
|
2005-07-22 |
2008-05-07 |
미리어드 제네틱스, 인크. |
높은 약물 충진 제형 및 투여형
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
US7772277B2
(en)
*
|
2005-08-04 |
2010-08-10 |
Transform Pharmaceuticals, Inc. |
Formulations comprising fenofibrate and a statin, and related methods of treatment
|
JP2008515931A
(ja)
*
|
2005-08-16 |
2008-05-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
結晶形ロスバスタチン中間体
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EP1919393A2
(en)
*
|
2005-09-01 |
2008-05-14 |
Prescient Medical, Inc. |
Drugs coated on a device to treat vulnerable plaque
|
US20080139457A1
(en)
*
|
2005-09-16 |
2008-06-12 |
Virginia Commonwealth University |
Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2007082264A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
MX2008013304A
(es)
|
2006-04-20 |
2008-10-27 |
Amgen Inc |
Compuestos de peptido 1 tipo glucagon.
|
US7659281B2
(en)
*
|
2006-04-25 |
2010-02-09 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors
|
WO2007139589A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US20080161324A1
(en)
*
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
WO2008044236A2
(en)
*
|
2006-10-10 |
2008-04-17 |
Dexcel Pharma Technologies Ltd. |
Improved release of statins in the intestine
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
TWI407955B
(zh)
|
2007-03-29 |
2013-09-11 |
Kowa Co |
高脂血症之預防及/或治療劑
|
WO2008130951A1
(en)
|
2007-04-17 |
2008-10-30 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
EP2166843A4
(en)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
WO2009018065A2
(en)
*
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
EP2209780B1
(en)
|
2007-11-01 |
2014-01-01 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
WO2009082437A2
(en)
|
2007-12-21 |
2009-07-02 |
Ligand Pharmaceuticals Incorporated |
Selective androgen receptor modulators (sarms) and uses thereof
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
AU2010229653A1
(en)
|
2009-03-27 |
2011-10-20 |
Astrazeneca Ab |
Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
US8470805B2
(en)
*
|
2009-04-30 |
2013-06-25 |
Kaohsiung Medical University |
Processes for preparing piperazinium salts of KMUP and use thereof
|
PT2435410T
(pt)
|
2009-05-28 |
2017-05-03 |
Bristol Myers Squibb Co |
Resumo
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
RU2564901C2
(ru)
|
2009-11-13 |
2015-10-10 |
Бристол-Майерс Сквибб Кампани |
Композиции метформина с уменьшенной массой
|
WO2011060256A2
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Bilayer tablet formulations
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP2013523894A
(ja)
|
2010-04-14 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼアクチベーターおよびその使用方法
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
CA2799708A1
(en)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phenyl benzoylamides
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
RU2016125229A
(ru)
|
2010-07-09 |
2018-12-04 |
БиЭйчВи ФАРМА, ИНК. |
Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
EP2626069A4
(en)
|
2010-10-06 |
2014-03-19 |
Univ Tokyo |
A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
TW201242953A
(en)
|
2011-03-25 |
2012-11-01 |
Bristol Myers Squibb Co |
Imidazole prodrug LXR modulators
|
US8586527B2
(en)
|
2011-10-20 |
2013-11-19 |
Jaipal Singh |
Cerivastatin to treat pulmonary disorders
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
WO2013102193A1
(en)
|
2011-12-29 |
2013-07-04 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
US8729092B2
(en)
*
|
2012-09-24 |
2014-05-20 |
Terence J. Scallen |
Rosuvastatin enantiomer compounds
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
US9200025B2
(en)
|
2012-11-20 |
2015-12-01 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
CN105209039B
(zh)
|
2013-03-15 |
2018-06-22 |
百时美施贵宝公司 |
Lxr调节剂
|
SG11201507496UA
(en)
|
2013-04-17 |
2015-11-27 |
Pfizer |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
CA2923272A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
US10822411B2
(en)
|
2014-09-15 |
2020-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
EP3811972B1
(en)
|
2015-02-27 |
2023-01-11 |
The Board of Trustees of the Leland Stanford Junior University |
Combination therapy for treatment of atherosclerosis
|
BR112017023158A2
(pt)
|
2015-04-30 |
2018-07-24 |
Harvard College |
anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
EP3630185A4
(en)
|
2017-05-30 |
2020-06-17 |
The Board of Trustees of the Leland Stanford Junior University |
TREATMENT OF NEURO-INFLAMMATORY DISEASE
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
SG11202102498UA
(en)
|
2018-09-26 |
2021-04-29 |
Lexicon Pharmaceuticals Inc |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
SG11202107614PA
(en)
|
2019-01-18 |
2021-08-30 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|